Heska (HSKA) Stock Rating Lowered by Zacks Investment Research

Heska (NASDAQ:HSKA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, January 3rd.

According to Zacks, “Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska’s state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company’s core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. “

Several other equities research analysts have also recently issued reports on HSKA. Canaccord Genuity initiated coverage on Heska in a report on Thursday, October 5th. They issued a “buy” rating and a $115.00 price objective on the stock. B. Riley reiterated a “hold” rating and issued a $96.50 price objective on shares of Heska in a report on Friday, October 27th. Raymond James Financial reiterated a “buy” rating on shares of Heska in a report on Monday, December 4th. BidaskClub lowered shares of Heska from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. Finally, Aegis reissued a “buy” rating on shares of Heska in a research note on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $113.30.

Heska (NASDAQ:HSKA) traded down $0.24 during trading hours on Wednesday, hitting $79.80. The stock had a trading volume of 46,683 shares, compared to its average volume of 78,688. Heska has a 52-week low of $75.21 and a 52-week high of $115.00. The firm has a market cap of $574.91, a PE ratio of 42.00, a PEG ratio of 2.11 and a beta of 0.74.

Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.03. Heska had a return on equity of 15.35% and a net margin of 10.67%. The company had revenue of $31.40 million for the quarter, compared to analysts’ expectations of $36.10 million. During the same period in the previous year, the firm posted $0.45 EPS. Heska’s revenue was down 6.0% compared to the same quarter last year. equities research analysts anticipate that Heska will post 2.03 earnings per share for the current year.

In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the transaction, the insider now directly owns 106,771 shares of the company’s stock, valued at approximately $9,304,024.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 14.70% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HSKA. Royal Bank of Canada raised its position in shares of Heska by 96.9% during the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock valued at $103,000 after buying an additional 499 shares during the period. Victory Capital Management Inc. raised its position in shares of Heska by 17.5% during the 2nd quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock valued at $116,000 after buying an additional 169 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Heska during the 3rd quarter valued at approximately $108,000. Municipal Employees Retirement System of Michigan purchased a new stake in shares of Heska during the 2nd quarter valued at approximately $154,000. Finally, BNP Paribas Arbitrage SA raised its position in shares of Heska by 59.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,858 shares of the medical research company’s stock valued at $190,000 after buying an additional 691 shares during the period. 80.89% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Heska (HSKA) Stock Rating Lowered by Zacks Investment Research” was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.truebluetribune.com/2018/01/20/heska-hska-stock-rating-lowered-by-zacks-investment-research.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply